Editors' ChoiceImmunology

What's in a Vaccine?

See allHide authors and affiliations

Science's STKE  02 Jan 2007:
Vol. 2007, Issue 367, pp. tw7
DOI: 10.1126/stke.3672007tw7

After vaccination, the efficiency with which protective antibodies are produced often depends on the presence of an adjuvant, a substance that promotes activation of antibody-producing B cells. It has been anticipated that Toll-like receptors (TLRs) might be major players in mediating the effects of adjuvants. However, Gavin et al. now find that the known TLR pathways do not modulate B cell responses, and so adjuvants containing TLR ligands must depend on other properties. Such a revision to thinking about the effects of TLR on B cell responses will likely refocus current thinking about vaccine development.

A. L. Gavin, K. Hoebe, B. Duong, T. Ota, C. Martin, B. Beutler, D. Nemazee, Adjuvant-enhanced antibody responses in the absence of Toll-like receptor signaling. Science 314, 1936-1938 (2006). [Abstract] [Full Text]

Stay Connected to Science Signaling